Quick Answer
PALVELLA THERAPEUTICS, INC. reported Operating Income Loss of -$38.60 million for the year ending 2025.
- PALVELLA THERAPEUTICS, INC. showed a decrease of -173.9% in Operating Income Loss from 2024 to 2025.
- This data is from PALVELLA THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2013 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$5.8 thousand | Q4 2013: -$2.2 thousand | Q1 2014: -$671.2 thousand | Q2 2014: -$2.77 million | Q3 2014: -$1.84 million | Q1 2015: -$3.70 million | Q2 2015: -$3.53 million | Q3 2015: -$3.88 million | Q1 2016: -$4.38 million | Q2 2016: -$5.80 million | Q3 2016: -$6.18 million | Q1 2017: -$8.01 million | Q2 2017: -$7.89 million | Q3 2017: -$5.18 million | Q1 2018: -$8.14 million | Q2 2018: -$2.24 million | Q3 2018: -$7.80 million | Q1 2019: -$10.68 million | Q2 2019: -$12.23 million | Q3 2019: -$2.91 million | Q1 2020: -$3.86 million | Q2 2020: -$4.66 million | Q3 2020: -$13.00 million | Q1 2021: -$5.06 million | Q2 2021: -$16.76 million | Q3 2021: -$19.01 million | Q1 2022: -$7.46 million | Q2 2022: -$12.33 million | Q3 2022: -$12.17 million | Q1 2023: -$15.51 million | Q2 2023: $2.06 million | Q3 2023: -$11.81 million | Q1 2024: -$1.76 million | Q2 2024: -$2.91 million | Q3 2024: -$5.06 million | Q1 2025: -$7.87 million | Q2 2025: -$9.25 million | Q3 2025: -$10.18 million.
- Over the full 15 years of available data (2013 to 2025), PALVELLA THERAPEUTICS, INC.'s Operating Income Loss has declined by 14,088,221.2%.
- Historical annual values: Fiscal year 2025: -$38.60 million | Fiscal year 2024: -$14.10 million | Fiscal year 2023: -$11.87 million | Fiscal year 2022: -$43.47 million | Fiscal year 2021: -$51.83 million | Fiscal year 2020: -$33.92 million | Fiscal year 2019: -$27.16 million | Fiscal year 2018: -$30.83 million | Fiscal year 2017: -$14.59 million | Fiscal year 2016: -$22.76 million | Fiscal year 2015: -$13.68 million | Fiscal year 2014: -$7.20 million | Fiscal year 2014: -$15.7 thousand | Fiscal year 2013: $553.8 thousand | Fiscal year 2013: -$274.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: